HIGHLIGHTS
- who: Dongshen Ma from the (UNIVERSITY) have published the article: Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma, in the Journal: (JOURNAL)
- how: The results showed that IGF1Rmutant tumors had a higher tumor mutation burden (TMB) in both the WES cohort and the MSKCC cohort (Fig 2A and 2B).
SUMMARY
Previous studies revealed IGF1R-mediated resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma. No study has reported the efficacy of immunotherapy in melanoma with IGF1R mutation. The results demonstrated that patients with IGF1R mutations . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.